NantOmics Overview
- Founded
- 2012

- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $251M

- Investors
- 2
NantOmics General Information
Description
Provider of molecular testing of cancer intended to offer a comprehensive personalized molecular system to inform cancer care. The company's molecular diagnostics approach combines DNA sequencing, RNA sequencing and quantitative proteomics to unearth the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells, enabling cancer patients to access personalized point of care.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Primary Office
- 9920 Jefferson Street
- Culver City, CA 90232
- United States
+1 (301) 000-0000
NantOmics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC | 18-Sep-2015 | $251M | 00000 | Completed | Generating Revenue | |
1. Early Stage VC (Series A) | 15-Jan-2015 | 0000 | 0000 | Completed | Generating Revenue |
NantOmics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of molecular testing of cancer intended to offer a comprehensive personalized molecular system to inform cancer
Biotechnology
Culver City, CA
00000
0000000000 0
00000
00000000
nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000000000 000000000
Cambridge, MA
0000
As of 0000
00000
00
0000-00-00
00000000000
00000000
erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
0000 000000000
Farmington, CT
0
As of 0000
00.000
00.00
0000-00-00
00000000000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialNantOmics Competitors (6)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Foundation Medicine | Corporate Backed or Acquired | Cambridge, MA | 0000 | 00000 | 00000000000 | |
00000000 00000000 | Venture Capital-Backed | Farmington, CT | 0 | 00.000 | 00000000000 | 00.000 |
00000000 000000 00 | Venture Capital-Backed | Baltimore, MD | 000 | 00000 | 0000000000 0 | 00000 |
0000000000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
00000000 | Formerly VC-backed | San Diego, CA | 0000 | 00000 | 000000&0 |
NantOmics Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Shahrooz Rabizadeh Ph.D | Chief Scientific Officer | ||
Patrick Soon-Shiong MD | Founder, Chief Executive Officer & Board Member |
NantOmics Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Patrick Soon-Shiong MD | Self | Founder, Chief Executive Officer & Board Member | 000 0000 |
NantOmics Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
California Capital Equity | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Relay Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
NantOmics Investments & Acquisitions (5)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 00000000 | 13-Apr-2017 | 000000000000000000 | Biotechnology | 0000000 0000-000000 00 | |
00000 00000000 | 02-Nov-2016 | 000000000 00000000 | 000 | Biotechnology | 0000000 0000-000000 00 |
000000000 | 18-Oct-2016 | 000000000 | 00.000 | Decision/Risk Analysis | |
00000000 000000000 | 10-Sep-2015 | 000000000000000000 | Diagnostic Equipment | 0000000 0000-000000 00 | |
OncoPlex Diagnostics | 01-Jan-2008 | Later Stage VC | 0000 | Diagnostic Equipment | 0000000 0000-000000 00 |